U.S. Physical Therapy, Inc. (USPH) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance, with significant revenue and margin growth, and positive developments in acquisitions and injury prevention. The Q&A indicates solid demand and effective labor management strategies, with AI tools enhancing efficiency. The introduction of a buyback program and slight commercial rate increases further boost sentiment. While there are some uncertainties, such as Medicare rate changes and staffing challenges, the overall outlook is optimistic. Given the company's small-cap status, the positive factors are likely to result in a stock price increase of 2% to 8%.
Key Financial Performance
Visits per clinic per day 32.7, up from last year's record of 30.6. The increase is attributed to happy patients who refer others and return for care.
Net Promoter Score 93.5, significantly higher than the healthcare industry average of 30-50. This reflects high patient satisfaction.
Injury Prevention Revenue Up 22.6% year-over-year. Gross profit increased by 25.8%. Growth driven by large contracts, including new ones in the auto industry.
Physical Therapy Revenue $168.3 million, a 17.3% increase year-over-year. Growth driven by acquisitions and exceeding 3 million visits year-to-date.
Medicare Cuts Impact $25 million impact this year, with $5-6 million year-over-year reduction. Despite this, revenue grew over 20%.
Salaries and Related Costs Increased slightly by 0.7% per visit, but overall cost per visit decreased slightly due to operational efficiencies.
Gross Profit Margin (Physical Therapy) 21.1%, up from 20.1% in the prior year quarter. Improvement attributed to revenue growth and cost management.
Adjusted EBITDA $26.9 million, up $4.7 million from the prior year quarter. Adjusted EBITDA margin expanded to 17.5% from 16.4%.
Workers' Compensation Revenue 10.4% of net patient revenues, with visits increasing 8.4% year-over-year. Focus on higher net rate business.
IIP Organic Revenue Growth 18.4% increase year-over-year. Gross profit up 21.8%. Margin improved to 22% from 21.4%.
Net Rate per Patient Visit $105.33, slightly up from $105.05 last year. Growth achieved despite Medicare rate reduction and policy changes in Michigan.
Operating Results $12.4 million, up from $11 million in the prior year quarter. Per share earnings increased to $0.81 from $0.73.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Net Promoter Score: Achieved a score of 93.5, significantly higher than the industry standard of 30-50, indicating high patient satisfaction.
Cash-based programs: Generated $900,000 in additional revenue, showing traction in new service offerings.
Industrial Injury Prevention (IIP) partnerships: Revenues increased by 22.6%, with gross profit up 25.8%. New large contracts in the auto industry are expected to drive further growth.
Physical therapy clinic expansion: Added over 50 net clinics compared to the prior year, exceeding 3 million visits year-to-date.
Operational cost management: Total operating costs per visit decreased year-over-year, and salaries increased by only 0.7%.
Adjusted EBITDA: Increased to $26.9 million, up $4.7 million from the prior year, with a margin expansion to 17.5%.
Acquisitions and home care business: Acquired Metro PT in New York, adding home care services and reporting 28,493 home care visits in Q2 2025.
Share repurchase program: Authorized a $25 million share repurchase program through December 31, 2026, while maintaining acquisitions as the primary capital allocation priority.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Medicare Cuts: Sequential Medicare rate cuts over the years have resulted in a cumulative impact of $25 million, with a $5-6 million year-over-year impact in 2025. This represents a significant headwind, reducing earnings by 8-8.5% compared to the prior year.
Staffing Challenges: Some markets are experiencing tight staffing conditions, which have constrained growth in mature facilities and impacted same-store growth, which was slightly over 1% but below normal expectations.
Regulatory and Payer Policy Changes: A 2.9% Medicare rate reduction at the beginning of the year and a policy change by the largest payer in Michigan negatively impacted net rates, creating additional financial headwinds.
Cost Management Pressures: While salaries and related costs increased slightly (0.7%), overall cost per visit decreased. However, managing costs effectively remains a challenge to sustain profitability.
Implementation Costs for New Systems: The company is incurring costs related to the implementation of a new enterprise-wide financial and human resources system, which will continue through 2026, adding to operational expenses.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Adjusted EBITDA Guidance: The company has increased its full-year 2025 adjusted EBITDA guidance to a range of $93 million to $97 million, up from the previous range of $88 million to $93 million.
Injury Prevention Business: The company plans to focus heavily on its injury prevention business due to its strong organic growth, high margins, and performance. It is expanding industry verticals and service offerings in this space and is competing for and winning large contracts.
Physical Therapy Business: The company expects continued growth in physical therapy revenues, driven by acquisitions and organic growth. It is also focusing on increasing reimbursement rates through targeted contract negotiations and growing its higher net rate workers' compensation business.
Cash-Based Programs: The company is rolling out cash-based programs, which have generated approximately $900,000 in additional revenue and are expected to continue ramping up.
Enterprise-Wide Financial and HR System: The company is in the early stages of implementing a new enterprise-wide financial and human resources system, with implementation costs expected to continue through 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The Board of Directors authorized a share repurchase program, providing the flexibility to repurchase up to $25 million of shares through December 31, 2026, if market conditions are appropriate. However, acquisitions will continue to be the primary capital allocation priority, consistent with the company's strategic growth strategy.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How would you characterize demand for your services and capacity constraints?
A:Demand is solid across most markets, but there is a balance to manage costs and meet demand. Some markets are tight and require additional FTEs, while others are being optimized. Cash-based programs are contributing additional revenue. De novo openings are on track to be the strongest year, with adjustments in recruiting and residency programs to meet demand.
Q:What was the rationale behind introducing a dividend and buyback program?
A:The dividend is ongoing and has been paid for a long time. The buyback is new and reflects management's belief in the company's undervaluation and growth potential. The first preference for capital deployment is injury prevention, followed by physical therapy. Share buybacks will be disciplined and depend on capital demands and stock valuation.
Q:Are AI tools being used to improve efficiency for physical therapists?
A:Yes, AI-backed technologies for clinical documentation are being deployed to reduce the time clinicians spend on documentation. Ambient listening AI tools are helping clinicians document more efficiently. Additionally, semi-virtualization of the front desk is being implemented to improve efficiency and reduce labor challenges.
Q:Can you provide an update on labor management strategies and turnover rates?
A:Investments in systems and resources in 2024 are paying off in 2025. There has been a 25% increase in student clinical rotations and the implementation of a new applicant tracking system. Mentorship programs are being expanded to connect clinicians across the company. Turnover rates are the lowest in the last 7 years. AI tools are also being used to improve retention by reducing documentation workload.
Q:What is the impact of Medicare rate changes for 2026?
A:The proposed Medicare rate changes for 2026 are expected to result in a 1% to 1.75% increase, translating to $2 million to $3 million in additional revenue and $1.5 million to $2.5 million in EBITDA. Management is pushing for further improvements and advocating for a multiyear plan to address systemic issues.
Q:How is the IIP segment performing and what are the future plans?
A:The IIP segment is performing ahead of budget with strong organic growth. Management is bullish on the segment and plans to continue deploying capital to develop it further. Seasonal patterns show strong performance throughout the year, except for slight dips in January and December.
Q:What is the status of the Metro acquisition and its impact?
A:The Metro acquisition is progressing well, with strong team performance and rate improvements. Net rates have increased from $101 to $107.50 per visit since the acquisition. De novo openings in the Metro area are contributing positively, and the acquisition is benefiting from higher rates in New York.
Q:What is the outlook for commercial pricing and payer dynamics?
A:Commercial rates increased by 1% to 1.5% year-over-year and 2.2% quarter-over-quarter. A payer issue in Michigan had a $0.30 per visit impact but is considered an isolated case. Management does not see a contagion effect and continues to focus on rate improvements.
Q:What are the capacity constraints and staffing challenges for de novo openings?
A:Capacity is not limited by physical footprint but by staffing availability. Incremental visits are margin accretive, and management is focused on recruiting and retaining staff through investments in mentorship, residency programs, and school affiliations. De novo openings are expected to be strong, supported by these initiatives.
Q:What is the company's approach to virtual PT applications and partnerships?
A:Management is open to partnerships with virtual PT providers but is cautious about the effectiveness of purely virtual solutions. The company is using augmented technology like Limber to enhance patient care and plans to develop a broader digital solution in the future.
Q:Review of Unclear Management Responses
A:Management avoided providing specific turnover numbers, stating they would be reported in the ESG at the end of the year. Additionally, they did not provide a detailed breakdown of the IIP segment's backlog or incremental revenue opportunities, citing staffing as a variable factor. They also refrained from quantifying the impact of cost-cutting initiatives and did not provide a clear outlook on the potential for a multiyear Medicare rate fix.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accounting Finance
Area today
Benjamin Rossi
Blair LLC
BofA Securities
Brian Gil
CEO Chairman
COO Corporate
Chairman Eric
Chief Officer
Co Research
Conference Instructions
Corporate Participant
Counsel Senior
Directors share
Division Brian
Division Conference
Division Jared
Inc
LLC Research
PT margin
Promoter Score
Reading
Research Division
Revenues
care visit
date
home care
implementation
life
mid
record visit
remainder
stat
story
summer
visit home
USPH Transcript
U.S. Physical Therapy, Inc. (USPH) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call summary shows mixed signals: financial performance was affected by weather and increased expenses, leading to a decrease in net income and cash reserves. However, the company maintains confidence in achieving its annual guidance and sees potential in hospital partnerships. The Q&A reveals concerns about unpredictable hospital deals and management's avoidance of detailed guidance. The market cap suggests moderate sensitivity to these factors. Overall, the sentiment is balanced, with positive long-term strategies offset by short-term financial challenges.
U.S. Physical Therapy, Inc. (USPH) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call showed strong financial performance with increased revenues, margins, and EBITDA. The Q&A highlighted positive growth prospects, efficient cost management, and strategic acquisitions. Despite some concerns about wage inflation and unclear details on hospital rates, the company's optimistic guidance, improved margins, and strategic initiatives like AI-driven operations and acquisitions suggest a positive outlook. Given the company's market cap, the stock is likely to see a positive movement of 2% to 8% over the next two weeks.
U.S. Physical Therapy, Inc. (USPH) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call summary and Q&A indicate positive sentiment due to increased EBITDA guidance, strong growth in the injury prevention segment, and favorable financial metrics. The prioritization of acquisitions over buybacks, efficient recruitment strategies, and sustainable growth in key segments further bolster this outlook. While there are some uncertainties, such as the Medicare rate impact, the overall sentiment remains positive, suggesting a likely stock price increase of 2% to 8% over the next two weeks, considering the company's small market cap.
U.S. Physical Therapy, Inc. (USPH) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call highlights strong financial performance, with significant revenue and margin growth, and positive developments in acquisitions and injury prevention. The Q&A indicates solid demand and effective labor management strategies, with AI tools enhancing efficiency. The introduction of a buyback program and slight commercial rate increases further boost sentiment. While there are some uncertainties, such as Medicare rate changes and staffing challenges, the overall outlook is optimistic. Given the company's small-cap status, the positive factors are likely to result in a stock price increase of 2% to 8%.
USPH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
